Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWeill Medical College of Cornell University
About this trial
The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age ≥ 18 years old.
Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and/or clinical criteria to undergo an endoscopy procedure (esophagoduodenoscopy and/or colonoscopy/flexible sigmoidoscopy), or endometrial screening procedure (transvaginal ultrasound and/or hysteroscopy and/or endometrial biopsy), OR
Individuals coming to Weill-Cornell Medicine/NYPH to undergo an endoscopy procedure, transvaginal ultrasound, or hysteroscopy for average-risk (population-based) recommendation OR
Individuals diagnosed with colorectal cancer or endometrial cancer coming to Weill- Cornell Medicine/NYPH for surgical treatment OR
Disqualifiers
None
Trial population
New York Presbyterian Hospital (NYPH) and Weill Cornell Medicine (WCM) Gastroenterology and Gynecologic Oncology Patients
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,120 Participants
are grouped into 6 trial groups6
Trial groupsSee each trial group below.
Group A: FAP without treatment with NSAIDs
Group B: FAP on treatment with NSAIDs
Group C: HNPCC without treatment with NSAIDs
Group D: HNPCC on treatment with NSAIDs
Group E: Other Hereditary Colorectal Cancer Syndromes
Group F: Average-risk population
Trial outcomes
Primary outcomes
1
Novel mechanisms and genes inducing genetic predisposition to Hereditary Cancer Syndromes
Discover novel mechanisms in intestinal carcinogenesis and genes inducing genetic predisposition to Hereditary Cancer Syndromes.
Time frame
7 years2
New genes and proteins for targeted therapy in Hereditary Cancer Syndromes
Identify new genes and proteins that are amenable to targeted therapy and precision prevention drug intervention and biomarker development in Hereditary Cancer Syndromes.
Time frame
7 years3
Understanding and learning about the immune system's ability to recognize and kill tumor cells
To facilitate understanding and learning about ways of how the immune system can be used to recognize and kill tumor cells that carry mutations.
Time frame
7 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Weill Medical College of Cornell University
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov